SCHEMBL2223914

SCHEMBL2223914

N#Cc1cccc(-n2ccc(=O)c(Cc3cccc(N(CCN4CCOCC4)C(=O)O)c3)n2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 2/20 0.40
CASR P41180 2/20 0.40
MET P08581 2/20 0.34
GRM5 P41594 1/20 0.34
KCNH2 Q12809 3/20 0.34
PIK3CD O00329 1/20 0.34
PIK3R2 O00459 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
PIK3CG P48736 1/20 0.34
PIK3R5 Q8WYR1 1/20 0.34
PIK3R3 Q92569 1/20 0.34
FNTA P49354 1/20 0.33
FNTB P49356 1/20 0.33
PGGT1B P53609 1/20 0.33
KCNJ1 P48048 1/20 0.33
CTSK P43235 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
ELANE P08246 1/20 0.33
USP2 O75604 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2365417 0.90 CACNA2D1 (0.38) CACNA2D1GRM5KCNH2KCNJ1DRD2
SCHEMBL2365418 0.90 CACNA2D1 (0.38) CACNA2D1GRM5KCNH2KCNJ1DRD2
SCHEMBL2220491 0.90 CACNA2D1 (0.36) CACNA2D1CASRGRM5KCNH2PIK3CD
SCHEMBL2275507 0.88 CACNA2D1 (0.40) CACNA2D1GRM5MAPK1
SCHEMBL2220660 0.86 SIGMAR1 (0.36) CASRSIGMAR1ALDH1A1CYP1A2CYP3A4
SCHEMBL13275002 0.86 CASR (0.36) CACNA2D1CASRMETSIGMAR1ALDH1A1
SCHEMBL2268510 0.85 CACNA2D1 (0.37) CACNA2D1GRM5USP2ALDH1A1CYP1A2
SCHEMBL2220317 0.85 GRM5 (0.38) CACNA2D1GRM5
SCHEMBL13275128 0.85 CACNA2D1 (0.41) CACNA2D1GRM5MAPK1
SCHEMBL13275099 0.84 CASR (0.36) CASRSIGMAR1SMN1; SMN2L3MBTL1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US claimed
WO-2011084402-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-14 WO claimed
EP-2515657-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2012-10-31 EP disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264735-A1 TYROSINE KINASE INHIBITORS ABL1, MET, ERBB2 CACNA2D1 4542/4885CASR 2573/4885MET 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.